Roivant Sciences Ltd.(ROIV)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ROIV Roivant Sciences Ltd.

交易中 09-03 15:12:56 EDT

34.20

+0.02

+0.04%

最高34.36	最低33.67	成交量194.39万
今开34.35	昨收34.18	日振幅2.00%
总市值247.03亿	流通市值198.67亿	总股本7.22亿
成交额6,632万	换手率0.33%	流通股本5.81亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":34.195,"timestamp":1788462776071,"preClose":34.18,"halted":0,"volume":1943860,"delay":0,"changeRate":0.00043885313048568075,"floatShares":581000000,"shares":722406273,"eps":-0.47,"marketStatus":"交易中","change":0.015,"latestTime":"09-03 15:12:56 EDT","open":34.35,"high":34.355,"low":33.67,"amount":66321289.99942,"amplitude":0.020041,"askPrice":34.2,"askSize":565,"bidPrice":34.19,"bidSize":1100,"shortable":3,"etf":0,"ttmEps":-0.47,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1788465600000},"marketStatusCode":2,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":34.18,"preHourTrading":{"tag":"盘前","latestPrice":33.79,"preClose":34.18,"latestTime":"09:25 EDT","volume":627,"amount":21209.370996,"timestamp":1788441900050,"change":-0.39,"changeRate":-0.01141,"amplitude":0.01141},"postHourTrading":{"tag":"盘后","latestPrice":34.18,"preClose":34.18,"latestTime":"19:30 EDT","volume":189285,"amount":6469734.0464,"timestamp":1788391804571,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.166788,"impliedVol":0.3701,"impliedVolPercentile":0.3254},"requestUrl":"/m/hq/s/ROIV","defaultTab":"news","newsList":[{"id":"1141500682","title":"Priovant宣布FDA批准Lisraya™（Brepocitinib）用于成人皮肌炎治疗；现已在美国上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1141500682","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141500682?lang=zh_cn&edition=full","pubTime":"2026-08-28 03:29","pubTimestamp":1787858949,"startTime":"0","endTime":"0","summary":"Priovant今日宣布，美国食品药品监督管理局（FDA）已正式批准Lisraya™（Brepocitinib）用于治疗成人皮肌炎患者。这一里程碑式的决定意味着该药物现已即刻在美国市场供应。\n皮肌炎是一种罕见的自身免疫性疾病，以肌肉无力和特征性皮疹为主要表现，长期以来困扰着众多患者。此次获批为这一患者群体带来了全新的治疗选择。\nLisraya™作为一种创新疗法，其获批上市标志着皮肌炎治疗领域取得了重大突破。该药物目前已可及，符合条件的患者将能够立即获得这一新的治疗方案的处方。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","PTH","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169456208","title":"《JAMA皮肤病学》发布Brepocitinib治疗皮肌炎3期VALOR试验皮肤特异性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1169456208","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169456208?lang=zh_cn&edition=full","pubTime":"2026-08-26 23:12","pubTimestamp":1787757130,"startTime":"0","endTime":"0","summary":"《JAMA皮肤病学》杂志正式刊发了Brepocitinib在皮肌炎治疗中的3期VALOR试验皮肤特异性结局数据。这项研究聚焦于皮肤相关症状的改善情况，为这一罕见自身免疫性疾病的治疗提供了新的临床证据。该试验结果此前已引起业界广泛关注，如今皮肤特异性数据的公布，进一步丰富了人们对Brepocitinib疗效维度的理解。皮肌炎以皮肤和肌肉炎症为特征，皮肤表现往往对患者生活质量造成显著影响，因此这一数据的发布具有重要临床意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","PTH","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187698206","title":"Roivant Sciences：Brepocitinib新药申请获批，皮肌炎产品预计2026年9月底前上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1187698206","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187698206?lang=zh_cn&edition=full","pubTime":"2026-08-06 19:29","pubTimestamp":1786015777,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. 传来重磅消息。其研发的Brepocitinib，在针对皮肌炎的治疗上，已提交新药申请（NDA）。公司预计，该药物有望在2026年9月底前获得批准，并正式推向市场。这无疑是一个关键节点，标志着这家生物制药公司，在自身免疫疾病领域的布局迈出了坚实一步。皮肌炎作为一种罕见的自身免疫性疾病，一直缺乏有效的治疗手段。Brepocitinib若能如期获批，将为患者带来新的希望。目前，市场正密切关注这一进展，并期待其最终结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176010812","title":"财报前瞻｜Roivant Sciences Ltd.本季度营收预计大幅下滑，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1176010812","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176010812?lang=zh_cn&edition=full","pubTime":"2026-07-30 10:01","pubTimestamp":1785376902,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.计划于2026年08月06日发布财报，市场聚焦费用端收缩与在研管线推进节奏对利润和现金流的影响。根据一致预期，本季度Roivant Sciences Ltd.预计总营收为2.06百万美元，同比下降71.57%；预计调整后每股收益为-0.32美元，同比变化为-2.18%；预计EBIT为-3.07亿美元，同比改善19.95%。基于近六个月的公开研报与观点收集，机构整体对Roivant Sciences Ltd.的短期基本面持偏谨慎态度，看空与中性观点合计比例高于看多。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Roivant Sciences Ltd.本季度营收预计大幅下滑，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170932235","title":"Roivant Sciences 将于2026年8月6日公布第一财季业绩并更新业务动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1170932235","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170932235?lang=zh_cn&edition=full","pubTime":"2026-07-24 04:06","pubTimestamp":1784837181,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.（ROIV）计划于2026年8月6日（周四）发布截至同年6月30日的第一财季财务报告。届时，公司还将同步提供最新的业务进展动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150102941","title":"异动解读 | Roivant Sciences盘中大涨15.99%，财报及关节炎药物进展提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1150102941","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150102941?lang=zh_cn&edition=full","pubTime":"2026-05-21 01:05","pubTimestamp":1779296717,"startTime":"0","endTime":"0","summary":"生物制药公司Roivant Sciences Ltd.（ROIV）今日盘中股价大幅上涨15.99%，表现强劲。消息面上，公司公布了截至2026年3月31日的第四季度及全年财务业绩，并同步更新了业务进展。尽管第四季度营收低于市场预期，但公司披露的业务动态获得了市场的积极评价。其中，路透社的市场快讯特别指出，其关节炎药物初步显示出积极效果，这一进展是推动股价走高的关键因素。Roivant Sciences是一家通过构建技术平台来加速开发变革性药物的公司，此次财报与研发进展的披露，显著增强了投资者对其未来增长潜力的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182026444","title":"异动解读｜Roivant Sciences盘中上涨11.1%，公布财年业绩及业务进展获市场积极反应","url":"https://stock-news.laohu8.com/highlight/detail?id=1182026444","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182026444?lang=zh_cn&edition=full","pubTime":"2026-05-20 21:40","pubTimestamp":1779284409,"startTime":"0","endTime":"0","summary":"5月20日，Roivant Sciences盘中上涨11.1%，报30.48美元/股，成交额3466.28万美元。消息面上，公司公布了截至3月31日的第四财季及全年财务业绩，并同步更新业务动态。尽管营收不及预期，但公司披露的业务进展获得市场积极反应，推动股价走强。Roivant Sciences是一家注册于百慕大的生物制药公司，通过构建技术平台和培养人才推出专注的生物制药及健康技术子公司，致力于更快开发变革性药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150457356","title":"异动解读｜Roivant Sciences盘前上涨8.12%，公布财年业绩及业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1150457356","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150457356?lang=zh_cn&edition=full","pubTime":"2026-05-20 19:38","pubTimestamp":1779277123,"startTime":"0","endTime":"0","summary":"5月20日，Roivant Sciences盘前上涨8.12%，报30.43美元/股，成交额170.13万美元。消息面上，公司公布了截至3月31日的第四财季及全年财务业绩。数据显示，第四财季持续运营每股收益为0.28美元，营收252万美元低于市场预期的382万美元。尽管营收不及预期，但公司同步披露的业务动态更新获得市场积极反应，推动股价走强。Roivant Sciences是一家注册于百慕大的生物制药公司，通过构建技术平台和培养人才推出专注的生物制药及健康技术子公司，致力于更快开发变革性药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174214400","title":"异动解读 | 公布财报及业务进展，Roivant Sciences盘前大涨9.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174214400","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174214400?lang=zh_cn&edition=full","pubTime":"2026-05-20 19:19","pubTimestamp":1779275955,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. (ROIV) 今日盘前股价大幅上涨9.89%，市场反应积极。消息面上，公司公布了截至2026年3月31日的第四季度及整个财年的财务业绩，并提供了最新的业务动态更新。这份财报和业务进展的披露，是推动股价在盘前交易时段走强的主要原因。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177836782","title":"Roivant公布2026财年第四季度及全年业绩，并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1177836782","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177836782?lang=zh_cn&edition=full","pubTime":"2026-05-20 19:01","pubTimestamp":1779274892,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. 已公布其截至2026年3月31日的第四季度及整个财年的财务业绩，同时提供了公司最新的业务动态更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131297163","title":"财报前瞻｜Roivant Sciences Ltd.本季度营收预计大幅下滑，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1131297163","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131297163?lang=zh_cn&edition=full","pubTime":"2026-05-14 00:02","pubTimestamp":1778688156,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.将在2026年05月20日美股盘前发布最新季度财报，市场普遍关注营收与亏损趋势及管线推进节奏。公司上季度披露的主营收入构成中，“产品”收入为2,093.60万美元，“许可、里程碑和其他”收入为385.10万美元。公司目前主营业务亮点在于“产品”带来的持续性收入，收入体量显著高于许可类收入。“产品”收入是目前公司最具可持续性的来源，上季度达2,093.60万美元，占收入的84.46%，显示商业收入已成为常态化支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Roivant Sciences Ltd.本季度营收预计大幅下滑，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178419514","title":"Roivant Sciences Ltd. 将于2026年5月20日公布2026财年第四季度及全年业绩并提供业务更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1178419514","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178419514?lang=zh_cn&edition=full","pubTime":"2026-05-12 04:06","pubTimestamp":1778530011,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. 宣布，公司计划于2026年5月20日（星期三）发布截至2026年3月31日的第四季度及整个2026财年的财务业绩报告。届时，管理层还将提供最新的业务进展与战略更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121877200","title":"Roivant Sciences Ltd：牛皮癣3期顶线数据与干燥综合征3期研究启动预计于2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1121877200","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121877200?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:03","pubTimestamp":1775120599,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.近日披露了其研发管线的重要进展时间表。根据公司规划，针对牛皮癣（Niu）适应症的3期临床试验顶线数据，以及针对干燥综合征（Cs）适应症的3期研究启动，均预计在2026年下半年的日历年内完成。\n这一系列关键节点的设定，标志着公司在自身免疫性疾病领域的研发进入了加速阶段。两项研究的推进，将为Roivant Sciences Ltd.的核心产品线带来重要的临床验证，并可能为未来的商业化奠定基础。市场投资者正密切关注这些里程碑事件，它们对公司估值和长期发展前景具有潜在的重大影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136481161","title":"Roivant拓展Brepocitinib研发计划：启动LPP新2B/3期试验并公布Batoclimax治疗TED的3期研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1136481161","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136481161?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:00","pubTimestamp":1775120417,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd. (ROIV) 宣布扩大其候选药物Brepocitinib的研发计划，将针对扁平苔藓样糠疹（LPP）开展一项新的2B/3期临床试验。同时，公司还公布了另一款药物Batoclimab用于治疗甲状腺眼病（TED）的3期研究结果。\n此次战略扩展彰显了Roivant致力于推进其创新疗法管线，以解决未满足的医疗需求。新启动的LPP试验旨在评估Brepocitinib对这一罕见炎症性瘢痕性脱发疾病的疗效与安全性。而Batoclimab在TED领域的积极3期数据，则为该药物的潜在应用提供了重要支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145816069","title":"《新英格兰医学杂志》发布Brepocitinib治疗皮肌炎的三期VALOR试验积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1145816069","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145816069?lang=zh_cn&edition=full","pubTime":"2026-03-29 03:01","pubTimestamp":1774724471,"startTime":"0","endTime":"0","summary":"《新英格兰医学杂志》近日刊发了Brepocitinib在治疗皮肌炎方面的三期VALOR临床试验的积极数据。该研究结果展现了该药物在应对这一自身免疫性疾病方面的显著潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516663104","title":"Roivant Sciences Ltd.盘中异动 下午盘股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516663104","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516663104?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:07","pubTimestamp":1741032469,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时07分，Roivant Sciences Ltd.股票出现波动，股价急速跳水5.03%。截至发稿，该股报10.20美元/股，成交量383.384万股，换手率0.54%，振幅5.77%。Roivant Sciences Ltd.股票所在的生物技术行业中，整体涨幅为0.17%。Roivant Sciences Ltd.公司简介：Roivant Sciences Ltd是一家处于商业阶段的生物制药公司，致力于改善向患者提供医疗保健。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304040749a25d9d08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304040749a25d9d08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117070208","title":"异动解读 | 生物技术股Roivant Sciences Ltd.(ROIV)盘中大涨5.51% 市场看好公司前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1117070208","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117070208?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:52","pubTimestamp":1739199156,"startTime":"0","endTime":"0","summary":"生物技术公司Roivant Sciences Ltd.今日盘中股价大涨5.51%,引发市场关注。这或与以下几个原因有关:. 首先,公司最新财报数据获得市场认可。公司继续积极推进旗下重磅药物如VTAMA、Batoclimab等的研发。其次,券商机构对ROIV股票给予了较高评级。这表明分析师看好ROIV的长期增长前景。最后,生物技术整个行业今日整体呈现上涨趋势,带动了ROIV作为龙头股的表现。如Ocean Biomedical、Biodexa等个股涨幅较大,再次证明该行业的资金持续保持流入态势。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510865319","title":"Roivant Sciences Ltd.盘中异动 早盘股价大涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510865319","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510865319?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:31","pubTimestamp":1739197919,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时31分，Roivant Sciences Ltd.股票出现波动，股价快速拉升5.10%。截至发稿，该股报11.45美元/股，成交量7.964万股，换手率0.01%，振幅1.26%。Roivant Sciences Ltd.股票所在的生物技术行业中，整体涨幅为0.38%。Roivant Sciences Ltd.公司简介：Roivant Sciences Ltd是一家处于商业阶段的生物制药公司，致力于改善向患者提供医疗保健。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223159988077f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223159988077f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191608976","title":"Roivant Sciences第三季度调整后每股亏损$(0.20)胜出预期$(0.28)，销售额900.2万美元未达预期1599.9万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191608976","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191608976?lang=zh_cn&edition=full","pubTime":"2025-02-10 20:17","pubTimestamp":1739189856,"startTime":"0","endTime":"0","summary":"Roivant Sciences  报告季度每股亏损$，优于分析师一致预期的$，相差28.57%。这一结果较去年同期的每股亏损$增长了4.76%。公司报告季度销售额为900.2万美元，未达到分析师一致预期的1599.9万美元，相差43.60%。这较去年同期的销售额1556万美元下降了42.05%。以上内容来自Benzinga Earnings专栏，原文如下：Roivant Sciences  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 28.57 percent. This is a 4.76 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $9.02 million which missed the analyst consensus estimate of $15","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences第三季度调整后每股亏损$(0.20)胜出预期$(0.28)，销售额900.2万美元未达预期1599.9万美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504449484","title":"特朗普2.0时代即将开启，投资机会如何掘金？","url":"https://stock-news.laohu8.com/highlight/detail?id=2504449484","media":"招商基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504449484?lang=zh_cn&edition=full","pubTime":"2025-01-20 10:36","pubTimestamp":1737340585,"startTime":"0","endTime":"0","summary":"美国候任总统唐纳德·特朗普将于美东时间1月20日12时正式宣誓就任美国第47任总统。特朗普2.0时代即将开启，有哪些投资机会可以布局？值得一提的是，科技股在特朗普任期内表现尤为突出，成为推动美股上涨的主要力量。在特朗普第一个任期内，美元整体表现相对弱势。4年任期内，美元指数累计下跌了10.53%。而纵观全球市场，在特朗普上一任期内，恒生科技指数涨幅超过147%，表现甚至略微优于纳斯达克指数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LECO","NVMI","PTC","ROIV","CHDN","MEDP","BK4561","HOLX","AEP","LNW","FSLR","OTEX","BK4581","AGNC","DPZ","EXE","BPMC","REGN","INTC","GTLB","MTSI","SWKS","CPRT","CME","DOX","NWSA","OKTA","MRNA","COST","NQmain","PCTY","NTAP","CEG","SOFI","SBUX","WTFC","LNT","DUOL","LSTR","ROST","TSCO","LPLA","EA","POOL","BPOP","PODD","INCY","QLD","TRMB","DASH","USAW.SI","MPWR","AMD","DOCU","ORLY","TER","TTWO","EXPE","RADX","PEP","CZR","INSM","NTES","META","HST","REG","PFG","APA","MANH","CFLT","EWBC","HQY","MNDY","HBAN","PAYX","LULU","FER","IDXX","AMZN","FSV","EVRG","AZN","LKQ","MKTX","NDAQ","BK4588","SEIC","MDB","FYBR","INTU","PAA","ALAB","BK4585","NBIX","SBAC","PCVX","ITCI","LIN","BRKR","FRPT","CRWD","BSY","MELI","NVIW.SI","SRPT","HON","CDNS","RIVN","ILMN","CBSH","TECH","BMRN","MCHP","CSCO","LU1815336091.USD","FTAI","Z","RYAAY","NTNX","ONC","BK4550","CSGP","ZM","RPRX","CYBR","TXN","ULTA","ROP","CDW","PCAR","AFRM","FOX","ISRG","NXPI","ON","WWD","RVMD","GILD","LSCC","AMGN","QID","CG","SMCI","TQQQ","TSYW.SI","RGLD","ICLR","ARGX",".IXIC","FWONK","CSX","MNQmain","GMAB","TPG","TSLA","SFM","BKR","JKHY","ALNY","LU0757428866.USD","EBAY","TROW","MRVL","TCOM","BIIB","NTRS","SAIA","ENPH","HOOD","CCEP","CHKP","SSNC","TTEK","JBHT","HSIC","JD","LAMR","CSWI","MARA","MKSI","AVGO","PLTR","PNFP","ADBE","GNTX","MTCH","ODFL","PARA","STLD","FOXA","OLED","TW","ESLT","AAL","CHTR","QQQ","NFLX","QCOM","WDC","FTNT","ADSK","WBA","MNST","ROKU","BK4593","WYNN","EQIX","SIRI","ZS","AUR","NDSN","MMYT","RGEN","MIDD","SNPS","TMUS","FCNCA","ANSS","QXO","FFIV","BK4534","KHC","BKNG","QRVO","ALGN","DDOG","AMAT","CHRW","ADI","PDD","CTAS","ENTG","STX","TTD","CTSH","ERIC","MDLZ","NTRA","ERIE","GLPI","CINF","HLNE","LU0053671581.USD","AAPL","LU2065731478.USD","AXON","TSEM","COO","BK4086","AKAM","CWST","CPB","TEAM","KDP","ASML","CHRD","COIN","DKNG","LOGI","AAON","MSFT","NICE","PSQ","GOOGL","DLTR","GEHC","GRAB","HTHT","USJW.SI","GEN","ARM","CASY","NVDA","LI","EXAS","SQQQ","FAST","TLN","DSGX","RKLB","COKE"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://roivant.com;investor.roivant.com","stockEarnings":[{"period":"1week","weight":-0.0699},{"period":"1month","weight":0.0258},{"period":"3month","weight":0.1575},{"period":"6month","weight":0.1876},{"period":"1year","weight":1.7587},{"period":"ytd","weight":0.5751}],"compareEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":0.0099},{"period":"3month","weight":0.0107},{"period":"6month","weight":0.138},{"period":"1year","weight":0.1951},{"period":"ytd","weight":0.1221}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Roivant Sciences Ltd.于2020年7月6日在百慕大注册成立。该公司是一家生物制药公司，旨在加速药物的开发和商业化。公司的研发管线包括brepocitinib（一种JAK1和TYK2小分子抑制剂，正在接受FDA审查用于治疗皮肌炎，并处于治疗非感染性葡萄膜炎、皮肤结节病和 lichen planopilaris的后期开发阶段）、IMVT-1402（一种针对FcRn的全人源单克隆抗体，正在开发用于治疗IgG介导的自身免疫适应症）以及mosliciguat（一种吸入式sGC激活剂，正在开发用于治疗间质性肺病相关的肺动脉高压）。公司通过创建灵活的子公司来推进其研发管线，以开发和商业化其药物和技术。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.071559},{"month":2,"riseRate":0.333333,"avgChangeRate":0.052607},{"month":3,"riseRate":0,"avgChangeRate":-0.087601},{"month":4,"riseRate":0.833333,"avgChangeRate":0.021573},{"month":5,"riseRate":0.5,"avgChangeRate":0.035469},{"month":6,"riseRate":0.833333,"avgChangeRate":0.042574},{"month":7,"riseRate":0.666667,"avgChangeRate":0.026843},{"month":8,"riseRate":0.666667,"avgChangeRate":0.010529},{"month":9,"riseRate":0.333333,"avgChangeRate":0.008705},{"month":10,"riseRate":0.6,"avgChangeRate":0.101456},{"month":11,"riseRate":0.8,"avgChangeRate":0.02515},{"month":12,"riseRate":0.8,"avgChangeRate":0.23185}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Roivant Sciences Ltd.(ROIV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Roivant Sciences Ltd.(ROIV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}